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Abstract 
The effects of mastoparan on phosphoinositide hydrolysis and prostaglandin E 2 (PGE 2) generation were investigated in astrocytes 
cultured from rabbit brain. Mastoparan i hibited the accumulations of [3H]inositol phosphates induced by bradykinin (1 /zM) in a time- 
and concentration-dependent manner. Mastoparan (3-30 /xM) also released PGE 2 in a time- and concentration-dependent manner. 
Mastoparan-induced release of PGE 2 was inhibited by indomethacin, a cyclooxygenase inhibitor, by dexamethasone, a steroidal 
anti-inflammatory drug, and by pertussis toxin, an inactivator of some G proteins, such as Gi and Go. Mastoparan also caused 
[3H]arachidonic a id liberation, which was inhibited by dexamethasone or pertussis toxin. In contrast, indomethacin, dexamethasone and 
pertussis toxin failed to attenuate mastoparan-induced inhibition of [3H]inositol phosphate accumulation i duced by bradykinin. Thus, 
mastoparan-induced inhibition of phosphoinositide hydrolysis does not involve pertussis toxin-sensitive G protein nor arachidonic acid 
metabolites. In addition to the inhibition of phospholipase C, mastoparan activates phospholipase A 2 through pertussis toxin-sensitive G 
protein. 
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1. Introduction 
Mastoparan, a venom toxin composed of 14 amino 
acids, has several pharmacological ctions, including his- 
tamine release from mast cells [1]. Since pertussis toxin 
eliminates mastoparan-induced histamine release [2], a GTP 
binding regulatory protein (G protein) may be involved in 
the actions of mastoparan. Higashijima et al. [3] demon- 
strate that mastoparan activates GTPase and GTP7 S bind- 
ing of purified G proteins, such as Go and Gi, in phospho- 
lipid vesicles. On the other hand, recent lines of evidence 
suggest hat phosphoinositide hydrolysis mediated through 
pertussis toxin-sensitive G protein comes from an activa- 
Abbreviations: BSA, bovine serum albumin; DMEM, Dulbecco's 
modified eagle's medium; EMEM, Eagle's minimum essential medium; 
G-protein, guanine nucleotide regulatory protein; GTPTS, guanosine 5'-3- 
(thio)triphosphate; H pes, 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid; MAPK, mitogen-activated protein kinase; PGE 2, prostaglandin E2; 
TCA, trichloroacetic acid. 
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tion of phospholipase C-fl2 by fly subunits dissociated 
from Gi [4,5]. Although many investigations have revealed 
that mastoparan activates phosphoinositide hydrolysis in 
several types of cells [6-8], we have previously demon- 
strated that mastoparan i hibits phosphoinositide hydroly- 
sis in 1321N1 human astrocytoma cells [9]. Mastoparan 
also inhibits the increase in intracellular Ca 2+ concentra- 
tions induced by carbachol or histamine [10], supporting 
the inhibitory effect of mastoparan on phosphoinositide 
hydrolysis. Similar results have been shown in permeabi- 
lized SH-SYSY cells [11] and HL-60 cells [12]. However, 
it remains unknown why mastoparan action on phospho- 
inositide hydrolysis hows cell type discrepancy. 
Astrocytes, which are assumed to exist 5-10 times 
more than neurons in brain, belong to a family of glial 
cells [13]. It has been reported that astrocytes have several 
receptors of neurotransmitters and autacoids [14-18], in- 
cluding arachidonic acid metabolites, uch as thromboxane 
A 2 receptors [19]. 1321N1 human astrocytoma cells have 
also been shown to express thromboxane A 2 receptors [20] 
in addition to other Ca 2+ mobilizing receptors, such as 
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muscarinic holinergic [21], Hi-histamine [22], bradykinin 
[23] and endothelin [24], of which stimulations result in 
activation of phosphoinositide hydrolysis. On the other 
hand, astrocytes themselves release prostaglandins (PGs) 
in response to several stimuli, such as ATP [25]. 
In the present study, we cultured astrocytes from rabbit 
brain and examined the effect of mastoparan on phospho- 
inositide hydrolysis, to clarify the cell type discrepancy of 
mastoparan action on phosphoinositide hydrolysis. We also 
examined the effect of mastoparan on prostaglandin E 2 
(PGE 2) generation in rabbit astrocytes. The results ob- 
tained suggest hat mastoparan i hibits phosphoinositide 
hydrolysis in a pertussis toxin-insensitive manner in rabbit 
astrocytes, upporting the previous results in 1321N1 hu- 
man astrocytoma cells. Fm~hermore, mastoparan activates 
phospholipase A 2 through pertussis toxin-sensitive G pro- 
tein. 
2.3. Assay of  [ 3H]inositol phosphates 
Phosphoinositide hydrolysis was monitored by determi- 
nation of [3H]inositol phosphates, described previously 
[9,20,26]. In brief, rabbit astrocytes were seeded into 12- 
well plates at the density of 105 cells per well. Two days 
after seeding cells, the medium was changed to DMEM 
containing 2 /xCi/ml of [3H]inositol for 18 h. The reac- 
tion was started by adding drugs in Eagle's minimum 
essential medium buffered by 20 mM Hepes to pH 7.35 
(EMEM-Hepes) in the presence of 10 mM LiCI. The 
reaction was terminated by addition of 5% trichloroacetic 
acid (TCA) after aspiration of the medium. The TCA 
extract was washed three times with ether, and applied to 
an anion exchange column (AG 1X-8, formate form). 
Total [3H]inositol phosphates were eluted by 1 M ammo- 
nium formate in 0.1 M formic acid, and counted by liquid 
scintillation counting. 
2. Materials and methods 2.4. Assay of  prostaglandin E 2 
2.1. Materials 
Mastoparan was purchased from Peptide Chemistry 
(Osaka, Japan). Bradykinin was from Sigma (St. Louis, 
MO, USA). Dulbecco's modified Eagle's medium 
(DMEM) and Eagle's minimum essential medium (EMEM) 
were obtained from Nissui Pharmaceuticals (Tokyo, Japan). 
Fetal calf serum (FCS) was from Cell Culture Laboratory 
(Cleveland, OH, USA). Pertussis toxin was from Fu- 
nakoshi (Tokyo, Japan). Indomethacin was from Wako 
Pure Chemicals (Osaka, Japan). Dexamethasone was from 
Banyu Pharm. (Tokyo, Japan). Prostaglandin E 2 (PGE 2) 
and anti-PGE 2 antibody were generous gifts from Ono 
Pharmaceuticals (Osaka, Japan). [3H]Myo-inositol was 
purchased from American Radiolabeled Chemicals (St. 
Louis, MO, USA). [3H]PGE2 was from NEN/DuPont 
(Boston, MA, USA). [3H]Arachidonic acid was from 
Moravek Biochemicals (Brea, CA, USA). 
2.2. Cell culture 
Rabbit astrocytes were cultured as described previously 
[19]. Briefly, the cerebral cortex of rabbit (2.5-3.0 kg) was 
cut into small pieces with scissors, and was treated with 
trypsin (0.02%) for 30 min. Then, the cells filtered by a 
nylon mesh were collected by centrifugation at 200 × g 
for 1 min and washed several times with DMEM buffered 
with 20 mM Hepes (pH 7.4). Then cells were suspended in
DMEM supplemented with 10% FCS in a concentration f
about 107/ml, and cultured in an incubator containing 5% 
CO z at 37°C. Cells were shaken for 24 h to remove 
oligodendrocytes 10-14 days after starting the culture. The 
medium was changed every 3-4 days. After 2-3 weeks, 
over 90% of the cells were astrocytes determined by 
anti-glial fibrillary acidic protein antibody. 
PGE 2 was analyzed by radioimmunoassay, described 
previously [27]. In brief, the cells were seeded into 12-well 
plates at the density of 105 cells per well. Two days after 
seeding cells, the cells were washed twice with EMEM- 
Hepes (pH 7.35), then the cells were preincubated for 10 
min at 37°C. After the cells were incubated with drugs for 
an additional 10 min, the medium was transferred into a 
tube. The medium containing PGE 2 was stored at -20°C 
until radioimmunoassay. The medium was acidified to pH 
4.0 by adding 1 N HCI, and PGE 2 was extracted twice by 
ethyl acetate. After drying ethyl acetate under reduced 
pressure, the sample was dissolved in 10 mM Tris-HC1 
(pH 7.6). The sample was incubated overnight at 4°C with 
[3H]PGE2 (10000 dpm) and anti-PGE 2 antibody (450 
times dilution) in a final volume of 300 /zl containing 
0.5% bovine serum albumin (BSA) in 100 mM Tris-HC1 
(pH 7.6). The free [3H]PGE2 was sedimented by centrif- 
ugation after adding 0.5 ml of the buffer containing 0.5% 
charcoal, 0.075% dextran and 0.5% BSA in 100 mM 
Tris-HC1 (pH 7.6). The [3H]PGE2 bound to antibody was 
counted by liquid scintillation counting. 
2.5. Arachidonic acid liberation 
The cells were seeded into 6-well plate at the density of 
2 × 105 cells per well. Three days after seeding cells, the 
cells were labeled with 3 /zCi/ml of [3H]arachidonic a id 
for 18 h. Then, the cells were washed twice with EMEM- 
Hepes (pH 7.35), and were preincubated for 10 min. After 
incubation with drugs for 10 min, the incubation medium 
was transferred to the tube containing an equi-volume of 
ice-cold chloroform/methanol/1 N HC1 (10/20/1).  
[3H]Arachidonic acid in chloroform was separated by 
thin-layer chromatography, using a silica gel plate (LK5D, 
Whatman Inc.) and a developer of benzene/dioxane/acetic 
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Fig. l. Effect of mastoparan on phosphoinositide hydrolysis and prostaglandin E 2 generation i  rabbit cultured astrocytes. (A) The cells were labeled with 
2 /xCi/ml of [3H]inositol for 18 h. After washing, the cells were incubated with mastoparan i the presence (Q)  or absence (O) of 1 /xM of bradykinin 
for 10 min. Analysis of [3H]inositol phosphates (IP) was described in Section 2 in detail. Each point represents he mean 4- S.E. from three determinations. 
* Significant difference from bradykinin alone (P < 0.05). (B) The cells were incubated with mastoparan at the indicated concentration for 10 min. 
Determination of prostaglandin E 2 (PGEe) was described in Section 2 in detail. Each point represents the mean 4- S.E. from three determinations. 
* Significant difference from without mastoparan (P < 0.05). 
acid = 60/30/3.  The portion corresponding to authentic 
arachidonic acid was scraped and counted by liquid scintil- 
lation counting. 
2.6. Drug treatment 
Dexamethasone or pertussis toxin was added to the 
culture medium 18 h before the experiment. When the 
cells were labeled with [3H]inositol or [3H]arachidonic 
acid, the drug was added simultaneously. The cells treated 
with dexamethasone or pertussis toxin were washed twice 
with EMEM-Hepes (pH 7.35) before starting the experi- 
ments. Indomethacin was added 20 min before the addition 
of other drugs. 
2.7. Data analysis 
The results obtained were expressed as mean_ S.E., 
and a significant difference (P  < 0.05) was analyzed with 
Student's t-test. 
3. Results 
3,1. Effect of mastoparan on phosphoinositide hydrolysis 
and prostaglandin E 2 release in rabbit astrocytes 
Stimulation of bradykinin receptor elicited phospho- 
inositide hydrolysis in rabbit astrocytes (Fig. 1A), similar 
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Fig. 2. Time course of mastoparan-induced inhibition of phosphoinositide hydrolysis and prostaglandin E 2 generation. (A) The cells were labeled with 2 
/xCi/ml of [3H]inositol for 18 h. After washing, the cells were incubated with mastoparan i  the presence (• )  or absence of ([]) of 1 /zM bradykinin, or 
withour mastoparan i  the presence (0 )  or absence (O)  of 1 /~M bradykinin. Each point represents he mean 4- S.E. from three experiments. * Significant 
difference between bradykinin alone and bradykinin plus mastoparan (P  < 0.05). (B) Cultured rabbit astrocytes were incubated with (O) or without (C)) 
30 p~M mastoparan for indicated time. Each point represents he mean 4- S.E. from three determinations. The prostaglandin E 2 (PGE 2) generation was 
maximum after 10 min incubation with mastoparan. * Significant difference from without mastoparan ateach time (P  < 0.05). 
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Fig. 3. Effect of indomethacin on mastoparan-induced inhibition of phosphoinositide hydrolysis and prostaglandin E 2 generation. (A) Inhibition of 
phosphoinositide hydrolysis by mastoparan (MP). Left: in the absence of indomethacin (IND). MP at the concentration f 30 /zM significantly inhibited 
bradykinin (BK)-induced phosphoinositide hydrolysis ( * P < 0.05). Right: MP also significantly inhibited BK-induced phosphoinositide hydrolysis in the 
presence of 5/xM IND ( * P < 0.05). (B) Prostaglandin E 2 (PGE2) generation i duced by 30 #zM MP. Left: in the absence of IND. Right: in the presence 
of 5/xM IND. * Significant difference (P < 0.05) from control. Note the IND attenuated MP-induced PGE 2 generation. Each column represents he mean 
with S.E. from three determinations. 
to in human astrocytoma cells [23]. Mastoparan in a con- 
centration range of 3-30 /zM did not activate or only 
slightly activates phosphoinositide hydrolysis, but it inhib- 
ited bradykinin-induced phosphoinositide hydrolysis in a 
concentration-dependent manner (Fig. 1A). Time course 
analysis revealed that mastoparan ata concentration f 30 
/zM inhibited bradykinin-induced phosphoinositide hydrol- 
ysis within 5 rain (Fig. 2A). The inhibition was clearly 
observed between 5-20 min. On the other hand, 
mastoparan released PGE 2 from astrocytes in a concentra- 
tion-dependent manner (Fig. 1B). Mastoparan-induced 
PGE 2 release appeared witlh the maximum of 10 min (Fig. 
2B). Mastoparan also inhibited ATP-induced phospho- 
inositide hydrolysis (Table 1), suggesting that the in- 
hibitory action of mastoparan might not be due to a 
blockade of bradykinin receptor. 
3.2. Effect of indomethacin o  mastoparan-induced inhibi- 
tion of phosphoinositide hydrolysis and prostaglandin E2 
release 
Since mastoparan stimulates PGE 2 release in addition 
to inhibition of phosphoinositide hydrolysis in rabbit astro- 
cytes, the role of arachidonic metabolites on phosphoinosi- 
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Fig. 4. Effect of dexamethasone on mastoparan-induced inhibition of phosphoinositide hydrolysis and prostaglandin E 2 generation (A) Inhibition of 
phosphoinositide hydrolysis by mastoparan (MP). Left: MP at the concentration of 30 /~M significantly inhibited l /~M bradykinin (BK)-induced 
phosphoinositide hydrolysis in the cells without dexamethasone (DEX) treatment (* P < 0.05). Right: MP also inhibited phosphoinositide hydrolysis 
significantly after the cells were treated with DEX for 18 h ( * P < 0.05). (B) Prostaglandin E 2 (PGE 2) generation i duced by 30 p~M MP. Left: MP (30 
~M) significantly ( * P < 0.05) stimulated PGE 2 generation i  the cells without reatment of DEX. Right: Effect of MP (30 /xM) after treatment of the 
cells with DEX (100 ng/ml) for 18 h. Note that DEX attenuated MP-induced PGE 2 generation. Each column represents he mean with S.E. from three 
determinations. 
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Table 1 
Effect of mastoparan o ATP-induced phosphoinositide hydrolysis 
Addition [ 3 H]Inositol phosphates 
(dpm/well) 
control 833.1 + 47.1 
Mastoparan (30/zM) 1184.9 + 49.0 
ATP (100/~M) 4949.9 + 49.4 a 
Mastopran (30/zM) 2754.5 + 52.3 a.b 
+ATP (100 ~M) 
Cells were labeled with [3H]inositol (2 /zCi/ml) for 18 h, and were 
incubated with mastoparan (30 /zM) and/or ATP (100 /zM) for 10 rain. 
Values represent mean+S.E, from three determinations, a Significant 
difference from control (P < 0.05); b significant difference from ATP 
alone (P < 0.05). 
tide hydrolysis was investigated (Fig. 3). Indomethacin (5 
/xM) potently inhibited mastoparan-induced PGE 2 release 
(Fig. 3B), while it did not modify the inhibitory effect of 
mastoparan on bradykinin-induced phosphoinositide hy- 
drolysis (Fig. 3A). 
dexamethasone potently inhibited mastoparan-induced 
PGE 2 release (Fig. 4B). 
3.4. Effect of pertussis toxin on mastoparan-induced inhi- 
bition of phosphoinositide hydrolysis and prostaglandin E 2 
release 
The treatment of the cells with pertussis toxin for 18 h 
resulted in a slight potentiation of bradykinin-induced 
phosphoinositide hydrolysis (Fig. 5A). The results indicate 
that bradykinin activates phospholipase C in a pertussis 
toxin-insensitive manner. Furthermore, pertussis toxin did 
not change mastoparan-induced inhibition of phosphoinosi- 
tide hydrolysis elicited by bradykinin (Fig. 5A). Pertussis 
toxin was potently effective in attenuating PGE 2 release in 
response to mastoparan (Fig. 5B). Pertussis toxin at the 
concentration of 3 ng /ml  caused about 60% reduction of 
mastoparan-induced PGE 2 release, indicating the involve- 
ment of a pertussis toxin-sensitive G protein in PGE 2 
release by mastoparan. 
3.3. Effect of dexamethasone on mastoparan-induced inhi- 
bition of phosphoinositide hydrolysis and prostaglandin E 2 
release 
The treatment of the astrocytes with dexamethasone, a 
synthetic steroid hormone used as an anti-inflammatory 
drug, for 18 h, did not modify the mastoparan-induced 
inhibition of phosphoinositide hydrolysis elicited by 
bradykinin, although it slightly inhibited bradykinin-in- 
duced phosphoinositide hydrolysis (Fig. 4A). However, 
3.5. Effects of dexamethasone and pertussis toxin on 
mastoparan-induced arachidonic acid liberation 
Mastopran at a concentration of 30 /zM liberated 
arachidonic acid significantly (Fig. 6). Pretreatment of 
cells with dexamethasone (100 ng /ml )  for 18 h resulted in 
the attenuation of mastopran-induced arachidonic acid lib- 
eration. The inhibitory potency of dexamethasone in
arachidonic acid liberation was weaker than that in PGE 2 
release (Fig. 4). Furthermore, the treatment of cells with 
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Fig. 5. Effect of pertussis toxin on mastoparan-induced inhibition of phosphoinositide hydrolysis and prostaglandin E 2 generation. (A) Inhibition of 
phosphoinositide hydrolysis by mastoparan (MP). Left: MP at the concentration f 30 /xM significantly inhibited 1 /xM bradykinin (BK)-induced 
phosphoinositide hydrolysis in the cells without pertussis toxin (PT) treatment (* P < 0.05). Right: MP also significantly inhibited phosphoinositide 
hydrolysis after the cells were treated with PT (100 ng/ml) for 18 h ( * P < 0.05). (B) Effect of PT on prostaglandin E 2(PGE 2) generation i duced by 30 
/xM MP. The cells were treated with PT at the concentrations of 3-100 ng/ml for 18 h. * Significant difference from MP alone without PT treatment 
(P < 0.05). Note that PT attenuated MP-induced PGE 2 generation. Each column represents the mean with S.E. from three determinations. 
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Fig. 6. Effects of dexamethasone and pertussis toxin on mastopran-in- 
duced arachidonic acid liberation. Left: Liberation of [3H]arachidonic 
acid by 30 /zM mastoparan (MP). Middle: liberation of 13H]arachidonic 
acid by 30 /zM mastoparan (MP) from the cells treated with dexametha- 
sone (DEX, 100 ng/ml). DEX si~:nificantly inhibited MP-induced libera- 
tion of [3H]arachidonic acid (* P < 0.05). Right: liberation of 
[3H]arachidonic acid by 30 /xM mastoparan (MP) from the cells treated 
with pertussis toxin (PT, 100 ng/ml). PT significantly inhibited MP-in- 
duced liberation of [3H]arachidonic acid (* P < 0.05). Each column 
represents he mean with S.E. from three determinations. 
pertussis toxin (100 ng/ml) for 18 h potently attenuated 
mastoparan-induced arachidonic acid liberation. 
4. Discussion 
The present study demonstrates that mastoparan i hibits 
agonist-induced phosphoinositide hydrolysis in rabbit as- 
trocytes, consistent with the previous results in 1321N1 
human astrocytoma cells [9,10]. In addition, mastoparan 
stimulates PGE 2 release in rabbit astrocytes. Cyclooxy- 
genase products are not involved in the mastoparan-in- 
duced inhibition of phosphoinositide hydrolysis, because 
indomethacin does not affect the inhibition. Mastoparan- 
induced PGE 2 release and inhibition of phosphoinositide 
hydrolysis have different mechanisms that can be discrimi- 
nated by pertussis toxin and/or dexamethasone. 
Although mastoparan stimulates phosphoinositide hy- 
drolysis in mast cells [6], PC-12 cells [8], rat hepatocytes 
[28] and rat parotid cells [7], it clearly inhibits phospho- 
inositide hydrolysis in rabbit astrocytes as well as in 
human astrocytoma cells [9]. Recent lines of evidence 
suggested that there are three pathways of phospholipase C 
activation. The first is tyrosine kinase-mediated activation 
of phospholipase C-y isozyme [29]. This pathway does not 
involve G protein, and is activated by growth factors. The 
second is phospholipase C-B activation by fly subunits of 
Gi, which is a pertussis toxin substrate [4,5]. The third is 
phospholipase C-il I activation by the a-subunit of  Gq/ll, 
which is not a substrate for pertussis toxin [30-32]. Since 
mastoparan has been shower to activate pertussis toxin-sen- 
sitive G protein selectively such as Gi and Go [3], and 
Gi-mediated phospholipase C activation is lacking in rab- 
bit astrocytes and human astrocytoma cells, then 
mastoparan does not activate phospholipase C in these 
cells. The exact mechanism of the inhibition of phospho- 
inositide hydrolysis by mastoparan i these cells remains 
unknown, so far. But there are a few possible mechanisms 
in the inhibition. The first is that the composition of 
phospholipids in membranes of astrocytes and/or astrocy- 
toma cells may be different from mast cells, and the 
pharmacological activity of mastoparan may be dependent 
on phospholipid composition, suggested by Raynor et al. 
[33]. The second is that mastoparan inhibits directly a 
Ca 2+ requiring phospholipase C by interfering with Ca 2+ 
utilization. In fact, it has been reported that mastoparan 
inhibits Ca2+/calmodulin [34]. However, mastoparan i - 
hibits GTPyS-induced activation of phospholipase C more 
potently than Ca 2+ (1 mM)-induced activation in mem- 
brane preparations of human astrocytoma cells [9] and 
HL-60 cells [12]. The third is that mastoparan activates a G 
protein that inhibits phospholipase C. To elucidate the 
exact mechanism of mastoparan-induced inhibition of 
phosphoinositide hydrolysis, further studies are necessary. 
Mastoparan activates phospholipase A 2, resulting in a 
liberation of arachidonic acid and a generation of PGE 2 in 
rabbit cultured astrocytes, as it does in fibroblasts [35,36]. 
Because dexamethasone inhibits PGE 2 release more po- 
tently than arachidonic acid liberation, dexamethasone may 
inhibit cyclooxygenase in addition to phospholipase A 2. In 
fact, it has been shown that dexamethasone inhibits the 
gene expression of prostaglandin endoperoxide-2 (induci- 
ble cyclooxygenase) in mesangial cells [37]. Since the 
arachidonic acid liberation and the PGE z release are inhib- 
ited by pertussis toxin, the site of action of mastoparan 
may be a G protein, which in turn secondarily activates 
phospholipase A 2. G protein-mediated activation of phos- 
pholipase A 2 in response to receptor stimulation has been 
shown in other cells, where the activation was also inhib- 
ited by pertussis toxin [38]. Although mastoparan is not a 
receptor agonist, it directly activates G proteins, like an 
activated receptor, as suggested by Higashijima et al. [3]. 
Our present finding, that mastoparan-induced arachidonic 
acid liberation and PGE 2 release are potently inhibited by 
pertussis toxin, supports the idea that mastoparan directly 
activates G protein. Therefore, mastoparan is a useful tool 
for analyzing the interaction of an activated receptor and G 
protein in a model system. On the other hand, recent lines 
of evidence have suggested that mitogen-activated protein 
kinase (MAPK) is involved in the process of phospho- 
lipase A 2 activation [39], and MAPK is activated through 
Gi and p21 ras pathway [40]. Because pertussis toxin in- 
hibits mastoparan-induced arachidonic acid liberation and 
PGE z release (Fig. 5), one of the mechanisms of 
mastoparan action might be through Gi-MAPK and phos- 
pholipase A 2. Since mastoparan still activates arachidonic 
acid liberation to a small extent even in the cells treated 
with high concentrations of pertussis toxin, further studies 
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are necessary to clarify the signal transduction of 
mastoparan-induced PGE 2 release in detail. In conclusion, 
mastoparan i hibits phosphoinositide hydrolysis in rabbit 
astrocytes with different mechanisms from activation of a 
pertussis toxin-sensitive G protein, and mastoparan also 
activates arachidonic acid liberation and PGE 2 release 
through a pertussis toxin-sensitive G protein. 
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